

Jian-Ping Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/652420/publications.pdf>

Version: 2024-02-01

46
papers

5,037
citations

186265

28
h-index

223800

46
g-index

47
all docs

47
docs citations

47
times ranked

6801
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Caregiving Hazardous to One's Physical Health? A Meta-Analysis.. Psychological Bulletin, 2003, 129, 946-972.	6.1	1,356
2	Development of the Chinese Personality Assessment Inventory. Journal of Cross-Cultural Psychology, 1996, 27, 181-199.	1.6	444
3	A Path Model of Chronic Stress, the Metabolic Syndrome, and Coronary Heart Disease. Psychosomatic Medicine, 2002, 64, 418-435.	2.0	382
4	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 2013, 16, 1205-1218.	2.1	257
5	Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research, 2012, 138, 18-28.	2.0	255
6	D ₂ Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. American Journal of Psychiatry, 2010, 167, 763-772.	7.2	192
7	White Matter Development in Adolescence: Diffusion Tensor Imaging and Meta-Analytic Results. Schizophrenia Bulletin, 2012, 38, 1308-1317.	4.3	190
8	Are Metabolic Risk Factors One Unified Syndrome? Modeling the Structure of the Metabolic Syndrome X. American Journal of Epidemiology, 2003, 157, 701-711.	3.4	175
9	Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 9-37.	3.3	173
10	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2016, 42, 1418-1437.	4.3	149
11	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. American Journal of Psychiatry, 2019, 176, 21-28.	7.2	127
12	Is Caregiving a Risk Factor for Illness?. Current Directions in Psychological Science, 2004, 13, 13-16.	5.3	119
13	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophrenia Bulletin, 2015, 41, 1227-1236.	4.3	100
14	Depressed Mood Mediates Decline in Cognitive Processing Speed in Caregivers. Gerontologist, The, 2009, 49, 12-22.	3.9	86
15	A meta-analysis of diffusion tensor imaging studies of the corpus callosum in schizophrenia. Schizophrenia Research, 2011, 129, 149-155.	2.0	85
16	Pharmacogenetics in psychiatry: translating research into clinical practice. Molecular Psychiatry, 2012, 17, 760-769.	7.9	76
17	Motivational Antecedents of Preventive Proactivity in Late Life: Linking Future Orientation and Exercise. Motivation and Emotion, 2005, 29, 438-459.	1.3	69
18	Neuropsychological Test Performance to Enhance Identification of Subjects at Clinical High Risk for Psychosis and Be Most Promising for Predictive Algorithms for Conversion to Psychosis. Journal of Clinical Psychiatry, 2017, 78, e28-e40.	2.2	68

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of factors associated with quality of life in first episode psychosis. <i>Schizophrenia Research</i> , 2018, 202, 26-36.	2.0	65
20	Association of a Schizophrenia Risk Variant at the <i>DRD2</i> Locus With Antipsychotic Treatment Response in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 1248-1255.	4.3	64
21	Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013, 146, 285-288.	2.0	58
22	A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16-week randomized placebo-controlled trial for participants concurrently treated with risperidone. <i>Schizophrenia Research</i> , 2019, 204, 295-303.	2.0	52
23	Pharmacogenetics of antipsychotics: recent progress and methodological issues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 183-191.	3.3	45
24	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. <i>Schizophrenia Bulletin</i> , 2015, 41, 1237-1247.	4.3	45
25	Meta-Analysis of Genetic Variation in DTNBP1 and General Cognitive Ability. <i>Biological Psychiatry</i> , 2010, 68, 1126-1133.	1.3	43
26	The COMT Met158 allele and violence in schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2012, 140, 192-197.	2.0	39
27	Hostility and Urine Norepinephrine Interact to Predict Insulin Resistance: The VA Normative Aging Study. <i>Psychosomatic Medicine</i> , 2006, 68, 718-726.	2.0	34
28	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 72, 1-10.	2.7	31
29	Joint Modeling of Longitudinal Changes in Depressive Symptoms and Mortality in a Sample of Community-Dwelling Elderly People. <i>Psychosomatic Medicine</i> , 2009, 71, 704-714.	2.0	30
30	Relations of caregiving stress and health depend on the health indicators used and gender. <i>International Journal of Behavioral Medicine</i> , 2006, 13, 173-181.	1.7	29
31	Lymphocyte proliferation is associated with gender, caregiving, and psychosocial variables in older adults. <i>Journal of Behavioral Medicine</i> , 2001, 24, 537-559.	2.1	24
32	A Cognitive Psychophysiological Model to Predict Functional Decline in Chronically Stressed Older Adults. <i>Journal of Clinical Psychology in Medical Settings</i> , 2007, 14, 177-190.	1.4	24
33	Association of SF-36 With Coronary Artery Disease Risk Factors and Mortality: A PreCIS Study. <i>Preventive Cardiology</i> , 2009, 13, no-no.	1.1	22
34	Recent Progress in Pharmacogenomics of Antipsychotic Drug Response. <i>Current Psychiatry Reports</i> , 2018, 20, 24.	4.5	22
35	BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. <i>Schizophrenia Research</i> , 2014, 152, 365-372.	2.0	20
36	The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 235-242.	1.5	15

#	ARTICLE	IF	CITATIONS
37	Effectiveness of a Cognitive Behavioral Weight Management Intervention in Obese Patients With Psychotic Disorders Compared to Patients With Nonpsychotic Disorders or No Psychiatric Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 458-464.	1.4	14
38	Sense of coherence buffers relationships of chronic stress with fasting glucose levels. <i>Journal of Behavioral Medicine</i> , 2001, 24, 33-55.	2.1	12
39	Suppressed Hostility Predicted Hypertension Incidence Among Middle-Aged Men: The Normative Aging Study. <i>Journal of Behavioral Medicine</i> , 2005, 28, 443-454.	2.1	10
40	Genetics of schizophrenia: What do we know?. <i>Current Psychiatry</i> , 2013, 12, 24-33.	1.7	9
41	Associations among gonadal hormone, triglycerides and cognitive decline in female patients with major depressive disorders. <i>Journal of Psychiatric Research</i> , 2021, 143, 580-586.	3.1	8
42	Are the salutogenic effects of social supports modified by income? A test of an "added value hypothesis".. <i>Health Psychology</i> , 2001, 20, 155-165.	1.6	8
43	The Benefits of Antipsychotic Drugs. , 2016, , 295-309.		4
44	Peripheral Blood Levels of Brain-Derived Neurotrophic Factor in Patients with First Episode Psychosis: A Systematic Review and Meta-Analysis. <i>Brain Sciences</i> , 2022, 12, 414.	2.3	3
45	Pharmacogenomics of Antipsychotic Drugs. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 127-138.	1.9	1
46	A simulations approach for meta-analysis of genetic association studies based on additive genetic model. <i>Meta Gene</i> , 2018, 16, 143-164.	0.6	1